News | Proton Therapy | October 25, 2018

Beaumont Hospital Cancer Institute Performs First Irradiation of Spot Scanning Proton Arc Therapy Plan

New proton therapy technique could enhance dose conformity at tumor level while reducing total patient dose

Beaumont Hospital Cancer Institute Performs First Irradiation of Spot Scanning Proton Arc Therapy Plan

October 25, 2018 — IBA announced the first irradiation of a Spot Scanning Proton Arc (SPArc) plan at the Beaumont Health Proton Therapy Center in Royal Oak, Mich., on its single-room proton therapy solution Proteus One.

Proton arc therapy has the possibility to further improve the quality of the treatment by enhancing the dose conformity at the tumor level while reducing the total dose received by the patient. In addition, the Spot-Scanning Proton Arc therapy technique potentially increases the robustness of the treatment plan and may further improve the adoption of dose escalation and hypofractionation. This first irradiation achieved is the result of a long-standing research and development program between IBA and Beaumont Health’s proton therapy team.

Craig Stevens, M.D., Ph.D., chairman, radiation oncology, Beaumont Health, commented: “Beaumont Health has been leading the research in radiotherapy for decades and we have been working closely on this innovative project with IBA. Combining our expertise will bring patient treatment using proton therapy to the next level. Proton arc therapy has been contemplated for some time. The recent improvements in beam quality and delivery are enabling us to develop a clinically viable product. Spot-Scanning Proton Arc (SPArc) therapy has the potential to allow proton therapy practitioners to improve dose conformity at the tumor while further reducing dose to surrounding healthy tissue and increasing treatment effectiveness.”

See an example of proton arc therapy in the VIDEO "Beaumont's Experience With Proton Therapy After One Year" — interview with Peyman Kabolizadeh, M.D., medical director, Beaumont Proton Therapy Center.

For more information: www.iba-worldwide.com

Related Content

Radiology, radiation therapy, PACS, Enterprise image, X-ray, DR Systems, CT, MRI, contrast, ultrasound, VNA, product comparisons, comparison charts on ITN magazine.
Feature | February 17, 2021
Imaging Technology News (ITN) maintains more than 40
Immunotherapy-based precision medicine clinical trials being developed

Getty Images

News | Prostate Cancer | February 16, 2021
February 16, 2021 — Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits fr

Images in 69-year-old man with biopsy-confirmed Gleason score 7 (3+4) prostate cancer. (a) Pretreatment axial T2-weighted fast spin-echo MRI scan (repetition time msec/echo time msec, 3820/97) shows tumor in midline anterior transition zone (arrow). (b) Intraoperative MRI scan shows contoured rectal wall (red line), prostate margin (blue outline), and region of interest (orange outline). Because the urethra was included in planned treatment volume, a suprapubic catheter was placed for continuous bladder drainage during treatment. (c) Intraoperative MRI scan shows focused ultrasound beam path (blue) overlaid on treatment plan. Rectangles illustrate each sonication spot. (d) Thermal map image obtained during treatment with heat deposition color coded in red overlaid on sonication spot. (e) Axial gadopentetate dimeglumine-enhanced MRI scan (230/2.97) obtained immediately after treatment shows devascularized ablated volume (arrows). (f) Corresponding T2-weighted fast spin-echo MRI scan (3820/97) at 5 months after ablation shows complete involution of transition zone. All seven cores from treatment area margins were negative for cancer at biopsy. Image courtesy of the Radiological Society of North America

News | Prostate Cancer | February 05, 2021
February 5, 2021 — A technique that delivers...
Real Time Imaging Technologies LLC iannounced that it has received U.S. Patent No. 10,898,070 IMAGING APPARATUS AND METHODS which covers the company’s methods for incorporating microlens into X-ray imaging detectors that enables significantly lower radiation dose without compromising image resolution.

Getty Images

News | Radiation Dose Management | February 05, 2021
February 5, 2021 — 
Ludwig Chicago Co-director Ralph Weichselbaum and Kaiting Yang, a postdoctoral researcher in Weichselbaum's lab.

Ludwig Chicago Co-director Ralph Weichselbaum and Kaiting Yang, a postdoctoral researcher in Weichselbaum's lab. Image courtesy of Ludwig Cancer Research

News | Radiation Therapy | January 28, 2021
January 28, 2021 — A study led by Ludwig Chicago